Company / Shareholders' Equity
Arrowhead Pharmaceuticals Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$466.1M
FY2025
5-year range
$185.4M / $466.1M
FY2021-FY2025
Trend
+151.3%
vs FY2024
Sector context
#101 of 213
Health Care
What the data says
At $466M, Arrowhead Pharmaceuticals's shareholders' equity ranks #101 of 213 in the Health Care sector. Shareholders' Equity returned to growth in FY2025 after 4 years of decline, reaching $466M.
Based on SEC 10-K filings.
$466M in FY2025 with a 5-year CAGR of +0.2%.
Improved from $271M to $466M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +5.4%
- 5-Year CAGR
- +0.2%
- 10-Year CAGR
- -
Sector benchmark
#101 of 213 in Health CareTop 47% of 213This company $466.1M Sector average $2.5B
▼
-81.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.2%, indicating consistent growth.
- In FY2025, shareholders' equity increased 151.3% year-over-year.
- Ranks #101 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $466.1M | +151.3% |
| FY2024 | $185.4M | -31.7% |
| FY2023 | $271.3M | -31.9% |
| FY2022 | $398.5M | -2.5% |
| FY2021 | $408.8M | -11.5% |
| FY2020 | $461.8M | +88.8% |
| FY2019 | $244.6M | +155.3% |
| FY2018 | $95.8M | +17.7% |
| FY2017 | $81.4M | -14.8% |
| FY2016 | $95.6M | -13.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026